During the past decade, Aarhus Universitetshospital Skejby; Blodsygdomme conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Aarhus Universitetshospital Skejby; Blodsygdomme" are "Diffuse Large B-cell Lymphoma" (1 trials), "Lymphoma" (1 trials) and "Non-Hodgkins Lymphoma" (1 trials). Many other conditions were trialed in "Aarhus Universitetshospital Skejby; Blodsygdomme" in a lesser frequency.

Most popular intervention types in "Aarhus Universitetshospital Skejby; Blodsygdomme" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Glofitamab" (3 trials), "Tocilizumab" (3 trials), "Obinutuzumab" (2 trials), "89Zr-Df-IAB22M2C" (1 trials) and "Atezolizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Aarhus Universitetshospital Skejby; Blodsygdomme" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Aarhus Universitetshospital Skejby; Blodsygdomme". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Aarhus Universitetshospital Skejby; Blodsygdomme, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Aarhus Universitetshospital Skejby; Blodsygdomme, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".